Taking the Pulse® Asia Gives Insight to How Physicians Use Technology

Manhattan ResearchManhattan Research, a global healthcare and pharmaceutical market research company, has announced the launch of Taking the Pulse® Asia, its latest physician market research and advisory service. The service is part of Manhattan Research's overall insight into global digital trends and focuses on physicians across Japan, China, South Korea, Taiwan, and Australia.

Healthcare and pharmaceutical marketers and other industry stakeholders will use Taking the Pulse® Asia to examine strategic technology, media, channel, and promotional mix trends as well as to benchmark their performance against industry competitors. Subscribers also have access to the Manhattan Research global analyst team for insights on using the market data to shape better-informed marketing and sales strategies.

Taking the Pulse® Asia covers topics such as:

  • Interest in Web 2.0 technologies for health and pharmaceutical information
  • Overall media consumption (traditional vs. new media)
  • Use and impact of sales representatives for clinical and pharmaceutical information
  • Internet access, frequency, types, and activities online
  • Mobile technology adoption, including PDAs/smartphones, MP3/iPods, and SMS messaging
  • Advanced online activities such as online video, blogs, podcasting, and wikis
  • Search engine reliance and frequency
  • Interest in health email newsletters, chat groups, and disease management tools

"This comprehensive review of both established and emerging markets in Asia provides our clients in the life sciences industry with a robust analysis of digital opportunities and the impact on sales and marketing today and in the near future," states Mark Bard, president of Manhattan Research. "After years of successfully providing strategic insight into the rapidly evolving markets in the United States and Europe, we are proud to offer this view of Japan, China, South Korea, Taiwan, and Australia to our clients. They demanded a global view of digital and global benchmarking metrics and we have delivered."

Mark Bard will be sharing physician digital marketing insights from Taking the Pulse® Asia and global trends at the upcoming eyeforpharma Pharma Marketing Excellence Japan conference, taking place February 3-4, 2009 at the Sheraton Miyako Hotel in Tokyo.

For additional Taking the Pulse® Asia product and subscription information, please visit http://www.manhattanresearch.com/products/physician/asia.aspx

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a global pharmaceutical and healthcare market research and strategic advisory firm. We conduct annual research studies covering eHealth trends among physicians and consumers in the United States, Europe, and Asia. For information, visit http://www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...